Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

Creative Commons License

Sylvester R. J., Brausi M. A., Kirkels W. J., Hoeltl W., Da Silva F. C., Powell P. H., ...More

EUROPEAN UROLOGY, vol.57, no.5, pp.766-773, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 57 Issue: 5
  • Publication Date: 2010
  • Doi Number: 10.1016/j.eururo.2009.12.024
  • Journal Name: EUROPEAN UROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.766-773
  • Keywords: Bacillus Calmette-Guerin, Epirubicin, Instillation therapy, Isoniazid, Non-muscle-invasive bladder cancer, Randomized clinical trial, Urothelial carcinoma of the bladder, MITOMYCIN-C, CLINICAL-TRIALS, EUROPEAN ORGANIZATION, FORMAL METAANALYSIS, III TRIAL, CANCER, CHEMOTHERAPY, PROGRESSION, RECURRENCE
  • Dokuz Eylül University Affiliated: Yes


Background: Intravesical chemotherapy and bacillus Calmette-Guerin (BCG) reduce the recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit of BCG relative to chemotherapy for long-term end points is controversial, especially in intermediate-risk patients.